Key AstraZeneca lung cancer treatment misses study goal
AstraZeneca said on Friday its immunotherapy drug Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares. (Source: Reuters: Health)
Source: Reuters: Health - November 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca's key lung cancer treatment fails main goal in late-stage trial
AstraZeneca's combination of two immunotherapy drugs did not meet the main goal in a closely watched late-stage study for certain type of stage IV lung cancer, the company said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - November 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca Mystic lung cancer trial fails to deliver results
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 16, 2018 Category: Pharmaceuticals Source Type: news

How Digital Health Technologies Could Make a Difference
Digital technologies are already changing healthcare. Adherium’s Hailie sensor, for instance, which transforms a traditional inhaler into a smart device, is already reportedly demonstrating reductions in emergency hospital visits. Mark Jones, vice president of R&D for Adherium, will share the story behind Hailie at BIOMEDevice San Jose’s Digital Health Product Spotlight on December 6. He’ll be joined by other digital technology trailblazers Angela McIntyre, executive director of eWear (Stanford Wearable Electronics Initiative); Chalisa Prarasri, CEO & co-founder...
Source: MDDI - November 15, 2018 Category: Medical Devices Authors: Daphne Allen Tags: BIOMEDevice San Jose Digital Health Source Type: news

AstraZeneca sells lung med to Sobi for $1.5 billlion
The company will gain an 8 percent ownership stake in Sobi with the deal's total value reaching $2.3 billion when including deferred and contingency payments (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 13, 2018 Category: Pharmaceuticals Source Type: news

Sobi(TM) to Acquire Synagis(R) US Rights From AstraZeneca - Creates a Platform for Global Growth
STOCKHOLM, Nov. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Swedish Orphan Biovitrum AB (publ) (Sobi¬ô) (STO:SOBI) has entered into agreements to acquire the perpetual rights to Synagis® (palivizumab) in the US from AstraZeneca and to partici... Biopharmaceuticals, Acquisitions Swedish Orphan Biovitrum, Sobi , AstraZeneca, Synagis, palivizumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 13, 2018 Category: Pharmaceuticals Source Type: news

AstraZeneca to divest US Synagis rights to Sobi
AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) to Swedish Orphan Biovitrum AB (publ) (Sobi). Sobi will commercialise Synagis in the US and around 130 AstraZeneca employees will transfer to Sobi as part of the transaction. (Source: World Pharma News)
Source: World Pharma News - November 13, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Sobi buys rights to AstraZeneca infant drug for $1.5 billion upfront
AstraZeneca has taken another step to refocus on priority drugs by selling U.S. rights to a treatment for infant lung infections to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion. (Source: Reuters: Health)
Source: Reuters: Health - November 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca sells infant drug rights to Sobi for $1.5 billion upfront
AstraZeneca took another step to refocus its portfolio on priority projects on Tuesday by selling U.S. rights to a treatment for a serious infant lung infection to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion. (Source: Reuters: Health)
Source: Reuters: Health - November 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca's diabetes drug curbs heart failure, kidney risks
The biggest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca's Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients. (Source: Reuters: Health)
Source: Reuters: Health - November 10, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca diabetes drug cuts complications
Farxiga reduces heart failure and kidney damage during clinical trials (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 10, 2018 Category: Pharmaceuticals Source Type: news

An Impatient Truth
15 years ago, I introduced the concept of patient centricity at our first ‘Patient Summits’ in London and Philadelphia. At the time, the idea was somewhat alien; pharmaceutical executives were more interested in patient compliance, the science of getting patients to take their medicine as instructed, and driving sales through repeat prescriptions.The existing language of the day was aggressive. It was all about ‘capturing’ market share and ‘dominating’ the minds of customers. I’ll never forget being berated by one delegate because a conference talk had deviated from the agenda &nda...
Source: EyeForPharma - November 9, 2018 Category: Pharmaceuticals Authors: Paul Simms Source Type: news

AstraZeneca: back from the abyss
Results may appear unimpressive but there is reason to be cheerful (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 8, 2018 Category: Pharmaceuticals Source Type: news

AstraZeneca shares surge as new drugs fuel growth
Drugmaker says its first quarter of product sales growth since 2014 ‘marks important day’ (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 8, 2018 Category: Pharmaceuticals Source Type: news

Greenberg Traurig London Team Represents Long-time Client AstraZeneca...
The London office of global law firm Greenberg Traurig LLP represented AstraZeneca AB on its agreement with Grünenthal to divest the European rights to Nexium for an upfront payment of USD700...(PRWeb November 08, 2018)Read the full story at https://www.prweb.com/releases/greenberg_traurig_london_team_represents_long_time_client_astrazeneca_ab_in_two_divestment_agreements/prweb15906696.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 8, 2018 Category: Pharmaceuticals Source Type: news

AstraZeneca sells 3 more drugs for $350 million
Covis Pharma will pay AstraZeneca $350 million for rights to Alvesco, Omnaris and Zetonna which are three older drugs for asthma and rhinitis (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 6, 2018 Category: Pharmaceuticals Source Type: news

Divestment of rights to Alvesco, Omnaris and Zetonna to Covis Pharma
AstraZeneca has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with rhinitis. (Source: World Pharma News)
Source: World Pharma News - November 6, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

AstraZeneca sells trio of respiratory drugs for $350m
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 6, 2018 Category: Pharmaceuticals Source Type: news

AstraZeneca sells drug rights for $815 million
The company will divest rights to Nexium in Europe and the global rights to Vimovo to Gr ünenthal (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 30, 2018 Category: Pharmaceuticals Source Type: news

Agreement with Gr √ľnenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US)
AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal. The medicines are outside AstraZeneca's three main therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory. (Source: World Pharma News)
Source: World Pharma News - October 30, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

AstraZeneca strengthens and expands oncology development and commercialisation collaboration with Innate Pharma
AstraZeneca, and its global biologics research and development arm MedImmune, announced a new multi-term agreement with Innate Pharma (Innate), building on an existing collaboration, aimed at accelerating each company's oncology portfolio and bringing new medicines to patients more quickly. (Source: World Pharma News)
Source: World Pharma News - October 24, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

AstraZeneca expands cancer immunotherapy with Innate deal
The drugmaker is buying a 9.8 percent stake in biotech company Innate Pharma, which is run by former AstraZeneca executive Mondher Mahjoubi (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 23, 2018 Category: Pharmaceuticals Source Type: news

AstraZeneca strengthens cancer focus with Innate deal
Drugmaker takes stake and extends tie-up with French biotech group (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 23, 2018 Category: Pharmaceuticals Source Type: news

In 2014 They Battled For Control. Now Pfizer's Read And AstraZeneca's Soriot In Different Places
Unfortunately, AstraZeneca ’s revenue predictions have not lived up to Soriot’s promise. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 23, 2018 Category: Pharmaceuticals Authors: John LaMattina, Contributor Tags: NYSE:PFE NYSE:AZN NYSE:NVS OTCMKTS:RHHBY Source Type: news

In 2014 They Battled For Control. Now Pfizer's Read And AstraZeneca's Soriot In Different Places
Unfortunately, AstraZeneca ’s revenue predictions have not lived up to Soriot’s promise. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 23, 2018 Category: Pharmaceuticals Authors: John LaMattina, Contributor Tags: NYSE:PFE NYSE:AZN NYSE:NVS OTCMKTS:RHHBY Source Type: news

AstraZeneca digs deeper into cancer with Innate stake
AstraZeneca is plowing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company. (Source: Reuters: Health)
Source: Reuters: Health - October 23, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca deepens partnership with Innate Pharma
Agreement will strengthen immuno-oncology collaboration (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 23, 2018 Category: Pharmaceuticals Source Type: news

Britain's AstraZeneca to buy 9.8 percent stake in France's Innate Pharma
British drugmaker AstraZeneca will buy a newly issued equity stake of 9.8 percent in smaller French peer Innate Pharma, as consolidation intensifies in the healthcare sector. (Source: Reuters: Health)
Source: Reuters: Health - October 23, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca sees strong ovarian cancer trial results
AstraZeneca ’s Lynparza greatly reduced the risk of ovarian cancer worsening in a phase III trial, helping the drugmaker take the lead against two U.S. rivals in the same class. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 22, 2018 Category: Pharmaceuticals Source Type: news

AstraZeneca gets cancer trial boost for Lynparza drug
Progression-free rates in trial point to potential as a breakthrough medicine (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 21, 2018 Category: Pharmaceuticals Source Type: news

AstraZeneca's Lynparza shown to put brakes on ovarian cancer
An AstraZeneca drug that blocks a cancer cell's ability to repair its genetic code greatly reduced the risk of ovarian cancer worsening in a phase III trial, underpinning its lead against two U.S. rivals in the same class. (Source: Reuters: Health)
Source: Reuters: Health - October 21, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

US FDA grants Lynparza Orphan Drug Designation for pancreatic cancer
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced that they were granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA) for Lynparza (olaparib) for the treatment of pancreatic cancer. (Source: World Pharma News)
Source: World Pharma News - October 18, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

AstraZeneca buoyed as Imfinzi cuts lung cancer deaths by a third
AstraZeneca's immunotherapy drug Imfinzi cut the risk of death in patients with mid-stage lung cancer by nearly a third in a closely watched clinical study, reinforcing the case for using the drug in earlier disease. (Source: Reuters: Health)
Source: Reuters: Health - September 25, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca Imfinzi scores lung cancer success
Increased survival rates and hopes of potential cure offer boost for drugmaker (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 25, 2018 Category: Pharmaceuticals Source Type: news

AstraZeneca immunotherapy drug cuts lung cancer deaths by almost a third
AstraZeneca's immunotherapy drug Imfinzi cut the risk of death in patients with mid-stage lung cancer by nearly a third in a closely watched clinical study, reinforcing the case for using the drug in earlier disease. (Source: Reuters: Health)
Source: Reuters: Health - September 25, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer
AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi during the Presidential Symposium of the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Toronto, Canada. (Source: World Pharma News)
Source: World Pharma News - September 25, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Trial results could give AstraZeneca diabetes drug edge over competitors
AstraZeneca reported positive results from a major study investigating the heart-protecting benefits of its diabetes drug, Farxiga. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 24, 2018 Category: Pharmaceuticals Source Type: news

EU approves AstraZeneca immunotherapy drug for lung cancer
AstraZeneca's immunotherapy drug Imfinzi has been approved in Europe for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body, the drugmaker said on Monday. (Source: Reuters: Health)
Source: Reuters: Health - September 24, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca diabetes drug cuts heart risks in major study
AstraZeneca said on Monday its diabetes drug Farxiga met a key goal in a major clinical study designed to show the heart-protecting benefits of the medicine. (Source: Reuters: Health)
Source: Reuters: Health - September 24, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca plots China robot offensive to counter price cuts
With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China. (Source: Reuters: Health)
Source: Reuters: Health - September 19, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca touts long-term safety, efficacy data for asthma biologic
AstraZeneca (NYSE:AZN) today touted results from a Phase III extension trial evaluating the long-term safety and efficacy of benralizumab as an add-on maintenance therapy for patients with severe eosinophilic asthma. Benralizumab, or Fasenra, is approved as an add-on maintenance treatment for severe eosinophilic asthma in an array of countries, including the U.S., the E.U., and Japan. Get the full story at our sister site, Drug Delivery Business News. The post AstraZeneca touts long-term safety, efficacy data for asthma biologic appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 18, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Wall Street Beat AstraZeneca plc Source Type: news

AstraZeneca sees positive late stage results for COPD
AstraZeneca reported that a phase 3 trial of a three-drug combination for the treatment of chronic obstructive pulmonary disease met eight out of its main objectives. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 17, 2018 Category: Pharmaceuticals Source Type: news

The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy in moderate to very severe chronic obstructive pulmonary disease
AstraZeneca today announced publication of results from the KRONOS Phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide/ glycopyrronium/formoterol fumarate) versus dual combination therapies Bevespi Aerosphere (glycopyrronium/formoterol fumarate), Symbicort Turbuhaler (budesonide/formoterol fumarate) and PT009 (budesonide/formoterol fumarate) in patients with (Source: World Pharma News)
Source: World Pharma News - September 17, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

05.01.12 -- AstraZeneca CEO Steps Down
05/01/12 Pharmaceutical Online Newsletter (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - September 15, 2018 Category: Pharmaceuticals Source Type: news

FDA approves AstraZeneca's drug for rare form of blood cancer
The U.S. Food and Drug Administration said on Thursday it approved AstraZeneca Plc's treatment for hairy cell leukemia, a slow-growing type of blood cancer. (Source: Reuters: Health)
Source: Reuters: Health - September 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

2018 Lasker Awards for basic and clinical medical research and special achievement
(Rubenstein Associates, Inc.) The Albert and Mary Lasker Foundation today announced the winners of its 2018 Lasker Awards: C. David Allis from Rockefeller University and Michael Grunstein from the University of California, Los Angeles will receive the Albert Lasker Basic Medical Research Award; John B. Glen, formerly from AstraZeneca, will be honored with the Lasker~DeBakey Clinical Medical Research Award; and Joan Argetsinger Steitz from Yale University will receive the Lasker~Koshland Special Achievement Award in Medical Science. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 11, 2018 Category: Biology Source Type: news

Tezepelumab granted Breakthrough Therapy Designation by US FDA
AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers. (Source: World Pharma News)
Source: World Pharma News - September 7, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype
Designation Supported by Phase 2b PATHWAY Data That Demonstrated Tezepelumab Significantly Reduced Asthma Exacerbations Compared to Placebo in Severe Asthma Patients THOUSAND OAKS, Calif., Sept. 6, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype. A Breakthrough Therapy Designation is designed to expedite the development and regulatory review of medicines that are intended to treat a serious condition...
Source: Amgen News Release - September 7, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Providence cancer spinoff charges ahead with immunotheapy drugs
Since Agonox did a deal with an AstraZeneca, the company has moved into new areas of research. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 5, 2018 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news

Providence cancer spinoff charges ahead with immunotheapy drugs
Since Agonox did a deal with an AstraZeneca, the company has moved into new areas of research. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 5, 2018 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news